|
| Status | Study title | Interventions | Country | Registered no. |
|
| Recruiting | Treatment of COVID-19 patients using Wharton’s jelly-mesenchymal stem cells | WJ-MSCs | Jordan | NCT04313322 |
| Completed | Study evaluating the safety and efficacy of autologous non-hematopoietic peripheral blood stem cells in COVID-19 | Autologous nonhematopoietic peripheral blood stem cells (NHPBSC) | United Arab Emirates | NCT04473170 |
| Not yet recruiting | Autologous adipose-derived stem cells (AdMSCs) for COVID-19 | Autologous adipose-derived stem cells | United States | NCT04428801 |
| Recruiting | Mesenchymal stem cell infusion for COVID-19 infection | Mesenchymal stem cells | Pakistan | NCT04444271 |
| Recruiting | Safety and efficacy study of allogeneic human dental pulp mesenchymal stem cells to treat severe COVID-19 patients | Allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC) | China | NCT04336254 |
| Not yet recruiting | Safety and efficacy of mesenchymal stem cells in the management of severe COVID-19 pneumonia | Umbilical cord-derived mesenchymal stem cells | Spain | NCT04429763 |
| Recruiting | MSCs in COVID-19 ARDS | Mesenchymal stromal cells | United States | NCT04371393 |
| Recruiting | Human umbilical cord mesenchymal stem cells (MSCs) therapy in ARDS (ARDS) | Umbilical cord-derived mesenchymal stem cell (UCMSCs) suspension | China | NCT03608592 |
| Recruiting | Mesenchymal stem cell for acute respiratory distress syndrome due for COVID-19 | Infusion IV of mesenchymal stem cells | Mexico | NCT04416139 |
| Not yet recruiting | NestaCell® mesenchymal stem cell to treat patients with severe COVID-19 pneumonia | NestaCell® | Brazil | NCT04315987 |
| Enrolling by invitation | A randomized, double-blind, placebo-controlled clinical trial to determine the safety and efficacy of Hope Biosciences Allogeneic Mesenchymal Stem Cell Therapy (HB-adMSCs) to provide protection against COVID-19 | HB-adMSCs | United States | NCT04348435 |
| Active, not recruiting | Use of mesenchymal stem cells in acute respiratory distress syndrome caused by COVID-19 | Mesenchymal stem cells derived from Wharton jelly of umbilical cords | Mexico | NCT04456361 |
| Recruiting | Clinical trial to assess the safety and efficacy of intravenous administration of allogeneic adult mesenchymal stem cells of expanded adipose tissue in patients with severe pneumonia due to COVID-19 | Allogeneic and expanded adipose tissue-derived mesenchymal stem cells | Spain | NCT04366323 |
| Enrolling by invitation | A clinical trial to determine the safety and efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy (HB-adMSCs) to provide protection against COVID-19 | HB-adMSCs | United States | NCT04349631 |
| Not yet recruiting | Novel coronavirus induced severe pneumonia treated by dental pulp mesenchymal stem cells | Dental pulp mesenchymal stem cells | China | NCT04302519 |
| Recruiting | Mesenchymal stem cell treatment for pneumonia patients infected with COVID-19 | MSCs | China | NCT04252118 |
| Not yet recruiting | Bone marrow-derived mesenchymal stem cell treatment for severe patients with coronavirus disease 2019 (COVID-19) | BM-MSCs | China | NCT04346368 |
| Active, not recruiting | Treatment with human umbilical cord-derived mesenchymal stem cells for severe corona virus disease 2019 (COVID-19) | UC-MSCs | China | NCT04288102 |
| Not yet recruiting | Study of human umbilical cord mesenchymal stem cells in the treatment of severe COVID-19 | UC-MSCs | China | NCT04273646 |
| Recruiting | Efficacy of intravenous infusions of stem cells in the treatment of COVID-19 patients | Intravenous infusions of stem cells | Pakistan | NCT04437823 |
| Enrolling by invitation | Treatment of Covid-19 associated pneumonia with allogenic pooled olfactory mucosa-derived Mesenchymal stem cells | Allogenic pooled olfactory mucosa-derivedmesenchymal stem cells | Belarus | NCT04382547 |
| Recruiting | Clinical research of human mesenchymal stem cells in the treatment of COVID-19 pneumonia | UC-MSCs | China | NCT04339660 |
| Active, not recruiting | Safety and effectiveness of mesenchymal stem cells in the treatment of pneumonia of coronavirus disease 2019 | Mesenchymal stem cells | China | NCT04371601 |
| Recruiting | Mesenchymal stem cell therapy for SARS-CoV-2-related acute respiratory distress syndrome | Cell therapy protocol 1
Cell therapy protocol 2 | Iran | NCT04366063 |
| Active, not recruiting | Role of immune and inflammatory response in recipients of allogeneic haematopoietic stem cell transplantation (SCT) affected by severe COVID19 | | United Kingdom | NCT04349540 |
| Recruiting | Administration of allogenic UC-MSCs as adjuvant therapy for critically-ill COVID-19 patients | Umbilical cord mesenchymal stem cells | Indonesia | NCT04457609 |
| Recruiting | Use of UC-MSCs for COVID-19 patients | Umbilical cord mesenchymal stem cells | United States | NCT04355728 |
| Recruiting | Efficacy and safety study of allogeneic HB-adMSCs for the treatment of COVID-19 | HB-adMSC | United States | NCT04362189 |
| Recruiting | Clinical use of stem cells for the treatment of Covid-19 | MSC treatment | Turkey | NCT04392778 |
| Not yet recruiting | Stem cell educator therapy treat the viral inflammation in COVID-19 | Combination product: stem cell educator-treated mononuclear cells apheresis | United States | NCT04299152 |
| Recruiting | Treatment of coronavirus COVID-19 pneumonia (pathogen SARS-CoV-2) with cryopreserved allogeneic P_MMSCs and UC-MMSCs | Placenta-derived MMSCs; cryopreserved placenta-derived multipotent mesenchymal stromal cells | Ukraine | NCT04461925 |
| Not yet recruiting | BAttLe against COVID-19 using mesenchYmal stromal cells | Allogeneic and expanded adipose tissue-derived mesenchymal stromal cells | United States | NCT04348461 |
| Not yet recruiting | Safety and efficacy of intravenous Wharton’s jelly derived mesenchymal stem cells in acute respiratory distress syndrome due to COVID 19 | Wharton’s jelly-derived mesenchymal stem cells | Colombia | NCT04390152 |
| Not yet recruiting | Use of hUC-MSC product (BX-U001) for the treatment of COVID-19 with ARDS | Human umbilical cord mesenchymal stem cells | United States | NCT04452097 |
| Recruiting | Pediatrics HOT COVID-19 database in NY tristate | | United States | NCT04445402 |
| Not yet recruiting | Using PRP and cord blood in treatment of Covid -19 | Stem cells | Egypt | NCT04393415 |
| Not yet recruiting | Study of the safety of therapeutic Tx with Immunomodulatory MSC in adults with COVID-19 infection requiring mechanical ventilation | BM-Allo.MSC | United States | NCT04397796 |
| Recruiting | Safety and efficacy of CAStem for severe COVID-19 associated with/without ARDS | CAStem | China | NCT04331613 |
| Recruiting | Mesenchymal stromal cell therapy for the treatment of acute respiratory distress syndrome | Mesenchymal stromal stem cells—KI-MSC-PL-205 | Sweden | NCT04447833 |
| Not yet recruiting | Mesenchymal stem cells (MSCs) in inflammation-resolution programs of coronavirus disease 2019 (COVID-19) induced acute respiratory distress syndrome (ARDS) | MSC | Germany | NCT04377334 |
| Recruiting | Efficacy and safety evaluation of mesenchymal stem cells for the treatment of patients with respiratory distress due to COVID-19 | XCEL-UMC-BETA | Spain | NCT04390139 |
| Not yet recruiting | Cellular immuno-therapy for COVID-19 acute respiratory distress syndrome—vanguard | Mesenchymal stromal cells | Canada | NCT04400032 |
| Not yet recruiting | ACT-20 in patients with severe COVID-19 pneumonia | ACT-20-MSC | United States | NCT04398303 |
| Not yet recruiting | Safety and feasibility of allogenic MSC in the treatment of COVID-19 | Mesenchymal stromal cell infusion | Brazil | NCT04467047 |
| Recruiting | Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) (COVID-19) | Human umbilical cord-derived CD362 enriched MSCs | United Kingdom | NCT03042143 |
| Not yet recruiting | Mesenchymal stromal cells for the treatment of SARS-CoV-2 induced acute respiratory failure (COVID-19 disease) | Mesenchymal stromal cells | United States | NCT04345601 |
| Recruiting | Treatment of severe COVID-19 pneumonia with allogeneic mesenchymal stromal cells (COVID_MSV) | Mesenchymal stromal cells | Spain | NCT04361942 |
| Recruiting | Double-blind, multicenter, study to evaluate the efficacy of PLX PAD for the treatment of COVID-19 | PLX-PAD | United States | NCT04389450 |
| Recruiting | Umbilical cord(UC)-derived Mesenchymal stem cells(MSCs) treatment for the 2019-novel coronavirus (nCOV) pneumonia | UC-MSCs | China | NCT04269525 |
| Recruiting | Cell therapy using umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2-related ARDS | Umbilical cord Wharton’s jelly-derived human | France | NCT04333368 |
| Recruiting | MultiStem administration for COVID-19 induced ARDS (MACoVIA) | MultiStem | United States | NCT04367077 |
| Not yet recruiting | Multiple dosing of mesenchymal stromal cells in patients with ARDS (COVID-19) | Mesenchymal stromal cells | United States | NCT04466098 |
| Not yet recruiting | A pilot clinical study on inhalation of mesenchymal stem cells exosomes treating severe novel coronavirus pneumonia | MSCs-derived exosomes | China | NCT04276987 |
| Not yet recruiting | A study to collect bone marrow for process development and production of BM-MSC to treat severe COVID19 pneumonitis | Bone marrow harvest | United Kingdom | NCT04397471 |
| Not yet recruiting | Organicell flow for patients with COVID-19 | Organicell flow (human amniotic fluid contain growth factors, cytokines, and chemokines as well as other extracellular vesicles/nanoparticles derived from amniotic stem and epithelial cells | United States | NCT04384445 |
|
